Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-07-19
2005-07-19
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S322000, C546S198000, C546S199000
Reexamination Certificate
active
06919355
ABSTRACT:
New Formula (I) compounds are disclosed having NR2B selective NMDA receptor antagonist activity:whereinone of the neighboring R1, R2, R3and R4groups is OH or NH2 and the others are each hydrogen , ortwo of the neighboring R1, R2R3and R4groups in given case together with one or more identical or different additional hetero atom and —CH═ and/or —CH2— groups forms a 5-6 membered homo- or heterocyclic ring, preferably pyrrole, pyrazole, imidazole, oxazole, oxo-oxazolidine, or 3-oxo-1,4-oxazine ring, and the other two of R1, R2, R3and R4groups are hydrogen atoms,R5and R6together with the nitrogen between them form a saturated or unsaturated, 4-6 membered heterocyclic ring, which is substituted by hydroxy group, and/or in given case phenyl or phenoxy, phenyl-(C1-C4alkyl), phenyl-(C1-C4alkoxy), phenoxy-(C1-C4alkyl), anilino, phenyl-(C1-C4alkylamino), [phenyl-(C1-C4alkyl)]-amino, benzoyl, hydroxy-diphenylmethyl, C1-C4alkoxycarbonyl-phenoxymethyl or benzhydrylidene group, optionally substituted on the aromatic ring by one or more halogen atom, cyano or hydroxy group, C1-C4alkyl or C1-C4alkoxy group,X is independently oxygen, —NH— or a CH2 group,Y is independently a nitrogen atom or a —CH— group, and the salts thereof formed with acids and bases.
REFERENCES:
patent: 5866589 (1999-02-01), Romero et al.
patent: 0 105 763 (1984-04-01), None
patent: WO 96/18628 (1996-06-01), None
patent: WO 98/14427 (1998-04-01), None
patent: WO 00/12074 (2000-03-01), None
patent: WO 00/00197 (2000-06-01), None
patent: WO 00/42213 (2000-07-01), None
Ennis et al. “Preparation of dioxino[2,3-e]indole . . . ” CA 115:279812 (1991).
Font et al. “Indole and pyridazino[4,5-b]indoles . . . ” CA 124:164316 (1996).
Berger et al. “Preparation of substituted aromatic . . . ” CA 135: 92639 (2001).
Andersson et al. “Preparation of heterocyclic pharmaceutical . . . ” CA 2001:816656 (2001).
XP-002191279 Chem. Abstracts (Indian J. Chem 1970).
XP-002191278 Chem.Abstract SVCE Columbus Ohio (ACTA Pol.Pharm 1974).
“Synthesis and Biological Evaluation of Novel Piperiodine . . . ” by Lubisch et al. (Biorg. & Med. Chem. Letters Oct. 2000.
Bioorganic & Medicinal Chemistry Letters 10 (2000) 483-486; Karan Milkiewicz et al; The design, synthesis and activity . . . .
Protein Science (1997) 6:1412-1417; Nickolay Chirgadze et al; The crystal structure of human α-thrombin . . . .
J. Med. Chem. 1996, 39, 3769-3789; Donna Romero et al; Targeting delavirdine/atevirdine resistant HIV-1: . . . .
J. Med. Chem. 1999, 42, 4140-4149; Michael Genin et al; Synthesis and structure—activity relationships . . . .
J. Med. Chem. 1978, vol. 21, No. 3, pp. 309-312; Piperidylalkylindoles. 1. Hypotensive activity . . . .
J. Med. Chem. 1992, 35, pp. 4903-4910; Ketanserin analogues: structure-affinity relationships for . . . .
TINS, vol. 10, No. 7, 1987, pp. 299-302; Excitotoxicity and the NMDA receptor.
Curr. Pharm. Des. 1999, 5, pp. 381-404; Antagonists selective for NMDA receptors containing . . . .
Stroke, 28, 1997, pp. 2244-2251; Effect of CP101,606, a novel NR2B subunit antagonist . . . .
Brain Res. 792, 1998, pp. 291-298; Effects of the NMDA antagonist CP-98,113 on regional . . . .
Exp. Neurol. 163, 2000, pp. 239-243; Antiparkinsonian actions of CP-101,606, an antagonist . . . .
Neuropharmacology 38, 1999, pp. 611-623; Selective NMDA NR2B antagonists induce . . . .
Drug News Perspect 11, 1998, pp. 523-569; Glutamate in CNS disorders as a target for . . . .
Eur. J. Neuroscience, vol. 10, 1998, pp. 1704-1715; Developmental changes in localization . . . .
Meth. Cell. Biol. 40, 1994, pp. 155-181; Practical aspects of measuring . . . .
J. Chem. Soc., 321, 1938, pp. 321-329; The unsaturation and tautomeric . . . .
J. Am. Chem. Soc., 80, 1958, pp. 1657-1662; Synthesis of some substituted . . . .
J. Org. Chem., 64, 1999, pp. 3763-3766; A practical synthesis of . . . .
J. Med. Chem., 18, 926 (1975), not yet provided.
Johnson, M.I., Bunge, R.P. (1992) 13-38, 51-75, Primary cell cultures of peripheral and central neurons and glia, not yet provided.
Helva. Chim. Acta., 1616 (1968), not yet provided.
Helva. Chim. Acta., 77, 100 (1994), not yet provided.
J. Chem. Soc. 1605-1608 (1948), not yet provided.
Tetrahedron 54, 13981, (1998), not yet provided.
Helva. Chim. Acta., 32, 135 (1949), not yet provided.
Bartane Szalai Gizella
Borza Istvan
Domany György
Farkas Sandor
Horvath Csilla
Chang Celia
Dubno Herbert
Myers Jonathan
Richter Gedeon Vegyeszeti Gyar Rt.
LandOfFree
Amide derivatives as NMDA receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Amide derivatives as NMDA receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amide derivatives as NMDA receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3369866